David J. Slotwiner

Learn More
This guideline contains hyperlinks to recommendations and supporting text that have been updated by the “2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)” (Circulation. 2011;123:104–123; doi:10.1161/CIR.0b013e3181fa3cf4) and the “2011 ACCF/AHA/HRS Focused Update on the Management of(More)
2011 WRITING GROUP MEMBERS L. Samuel Wann, MD, MACC, FAHA*, Chair; Anne B. Curtis, MD, FACC, FAHA*†; Craig T. January, MD, PhD, FACC*†; Kenneth A. Ellenbogen, MD, FACC, FHRS†‡; James E. Lowe, MD, FACC*; N.A. Mark Estes III, MD, FACC, FHRS§; Richard L. Page, MD, FACC, FHRS†‡; Michael D. Ezekowitz, MB, ChB, FACC*; David J. Slotwiner, MD, FACC‡; Warren M.(More)
Idiopathic ventricular tachycardia (VT) is characterized by two predominant forms. The most common form originates from the right ventricular outflow tract and presents as repetitive monomorphic VT or exercise-induced VT. The tachycardia is adenosine sensitive and is thought to be because of cAMP-mediated triggered activity. The other major form of(More)
Nonlinear-dynamical control techniques, also known as chaos control, have been used with great success to control a wide range of physical systems. Such techniques have been used to control the behavior of in vitro excitable biological tissue, suggesting their potential for clinical utility. However, the feasibility of using such techniques to control(More)
BACKGROUND Clinical studies have shown that biphasic shocks are more effective than monophasic shocks for ventricular defibrillation. The purpose of this study was to compare the efficacy of a rectilinear biphasic waveform with a standard damped sine wave monophasic waveform for the transthoracic cardioversion of atrial fibrillation. METHODS AND RESULTS(More)
OBJECTIVES We assessed the impact of antihypertensive treatment in hypertensive patients with electrocardiographic (ECG) left ventricular (LV) hypertrophy and a history of atrial fibrillation (AF). BACKGROUND Optimal treatment of hypertensive patients with AF to reduce the risk of cardiovascular morbidity and mortality remains unclear. METHODS As part(More)
BACKGROUND CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A(1)-adenosine receptor agonist with potential potent antiarrhythmic effects in tachycardias involving the atrioventricular (AV) node. This study, the first in humans, was designed to determine the effects of CVT-510 on AV nodal conduction and hemodynamics. METHODS AND(More)